Followers | 18 |
Posts | 1300 |
Boards Moderated | 0 |
Alias Born | 04/09/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, July 13, 2017 3:37:40 PM
Throughout 2017, we expect to continue actively marketing Nyloxin® and Pet Pain-AwayTM as well as beginning sales of Nyloxin® Military Strength. It is our goal to begin broad retail sales of our OTC products and get Nyloxin® and Pet Pain-Away into retail stores by the end of 2017. These sales will bring in the revenue that will bring the company to profitability as well as provide the financing for the proposed clinical studies. We have worked diligently with our partners to move the registration process forward in Canada. We have also worked with distributors in Mexico, Spain and Israel. All of these markets should provide revenue growth throughout 2017.
http://www.nutrapharma.com/Dec2016_shareholder_letter.pdf
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM